Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products, and titanium products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.

ATI Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ANNUAL SALES OF $4.6 BILLION REPRESENT HIGHEST TOTAL SINCE 2012 Q4 2025 SALES OF $1.2 BILLION AND FISCAL YEAR 2025 SALES OF $4.6 BILLION Q4 2025 NET INCOME ATTRIBUTABLE TO ATI OF $97 MILLION, OR $0.69 PER SHARE; FISCAL YEAR 2025 NET INCOME ATTRIBUTABLE TO ATI OF $404 MILLION, OR $2.85 PER SHARE SALES TO THE AEROSPACE & DEFENSE MARKET REPRESENT 68% OF Q4 2025 SALES, UP FROM 65% OF Q4 2024 SALES FISCAL YEAR 2025 OPERATING CASH FLOW OF $614 MILLION, UP FROM $407 MILLION FOR FISCAL YEAR 2024 NON-GAAP INFORMATION(A) Q4 2025 ADJUSTED NET INCOME ATTRIBUTABLE TO ATI(A) OF $130 MILLION, OR $0.93 PER SHARE Q4 2025 ADJUSTED EBITDA(A) OF $232 MILLION, OR 19.7% OF SALES FISCAL YEAR 2025 ADJUSTED FREE CASH FLOW(A) OF $380 MILLION, UP 53% OVER FISCAL YEAR 2024 GUIDANCE THE COMPANY IS PROVIDING FIRST QUARTER AND FISCAL YEAR 2026 GUIDANCE IN THE TABLE BELOW. CURRENT GUIDANCE Q1 2026 FISCAL YEAR 2026 ADJUSTED EBITDA(B) $216M - $226M $975M - $1,025M ADJUSTED EARNINGS PER SHARE(B) $0.83 - $0.89 $3.99 - $4.27 ADJUSTED FREE CASH FLOW(B) $430M - $490M (A) RECONCILIATIONS OF THE REPORTED INFORMATION UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES (GAAP) TO NON-GAAP FINANCIAL MEASURES ARE INCLUDED IN ACCOMPANYING FINANCIAL TABLES.

ATI ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2025 RESULTS

WAYNE, PA., JAN. 12, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED THAT IT HAS INITIATED A PLACEBO-CONTROLLED PHASE 1B PROOF-OF-CONCEPT (POC) TRIAL IN ATOPIC DERMATITIS (AD) FOR ATI-052, THE COMPANY'S POTENTIAL BEST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTI-TSLP/IL-4R ANTIBODY. WE ARE EXPERIENCING STRONG MOMENTUM IN THE ATI-052 CLINICAL DEVELOPMENT PROGRAM INCLUDING THE RECENT POSITIVE PHASE 1A INTERIM RESULTS WHICH DEMONSTRATED A STRONG SAFETY AND TOLERABILITY PROFILE, EXTENDED PHARMACOKINETICS, AND CONCENTRATION-DEPENDENT PHARMACODYNAMICS EVEN AT THE LOWEST DOSE, SAID DR. JESSE HALL, CHIEF MEDICAL OFFICER OF ACLARIS.

ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN ATOPIC DERMATITIS (AD) WITH ITS NOVEL BISPECIFIC ANTIBODY ATI-052

FRIENDSHIP, N.Y., JAN. 09, 2026 (GLOBE NEWSWIRE) -- WHAT ARE THE MOST COMMON MISTAKES PEOPLE MAKE WHEN IT COMES TO LIFE INSURANCE?

INSURANCE EXPERT MICHELLE HALL OF ALLEGHENY COUNTY OUTLINES COMMON LIFE INSURANCE MISTAKES FOR HELLONATION

- POSITIVE INTERIM RESULTS OF PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL REINFORCE POTENTIAL BEST-IN-CLASS POTENCY ADVANTAGE OF ATI-052 - - TRIAL RESULTS SUPPORT POTENTIAL FOR EXTENDED DOSING OF UP TO EVERY THREE MONTHS - - INITIATION OF PHASE 1B PROOF-OF-CONCEPT (POC) TRIALS IN ATOPIC DERMATITIS (AD) AND ASTHMA NOW EXPECTED IN FIRST QUARTER OF 2026; PLANNING UNDERWAY FOR ADVANCEMENT OF ATI-052 INTO PHASE 2B TRIAL IN AD IN THE SECOND HALF OF 2026 - - MANAGEMENT TO HOST A CONFERENCE CALL TO DISCUSS UPDATE TODAY AT 8:00 AM EST - WAYNE, PA., JAN. 06, 2026 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED POSITIVE INTERIM RESULTS FROM THE FIRST-IN-HUMAN PHASE 1A SINGLE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) TRIAL OF ITS ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052.

ACLARIS THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 1A TRIAL OF ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 SUPPORTING EXPEDITED CLINICAL DEVELOPMENT

DALLAS , DEC. 22, 2025 /PRNEWSWIRE/ -- ATI (NYSE: ATI) HAS SCHEDULED THE LIVE WEBCAST FOR ITS FOURTH QUARTER AND FULL YEAR 2025 EARNINGS CONFERENCE CALL ON TUESDAY, FEBRUARY 3, 2026, AT 7:30 A.M. CT (8:30 A.M.

ATI ANNOUNCES WEBCAST FOR FOURTH QUARTER AND FULL YEAR 2025 RESULTS

PROVEN ATI LEADER BRINGS OPERATIONAL DEPTH AND FINANCIAL DISCIPLINE TO DRIVE NEXT PHASE OF GROWTH DALLAS , DEC. 8, 2025 /PRNEWSWIRE/ -- ATI INC. (NYSE: ATI) ANNOUNCED THAT JAMES ROBERT "ROB" FOSTER WILL BECOME SENIOR VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2026. FOSTER SUCCEEDS DON NEWMAN, WHO WILL SERVE AS STRATEGIC ADVISOR TO THE CEO BEGINNING JANUARY 1.

ATI NAMES J. ROBERT FOSTER AS CHIEF FINANCIAL OFFICER

ROBERT S. WETHERBEE TO RETIRE AS EXECUTIVE CHAIR AND BOARD MEMBER DALLAS , NOV. 18, 2025 /PRNEWSWIRE/ -- ATI INC. (NYSE: ATI) ANNOUNCED THAT THE BOARD OF DIRECTORS HAS ELECTED KIMBERLY A. FIELDS TO BECOME BOARD CHAIR OF ATI, IN ADDITION TO HER ROLES AS CHIEF EXECUTIVE OFFICER AND PRESIDENT.

ATI PRESIDENT AND CEO KIMBERLY A. FIELDS ELECTED BOARD CHAIR

- POSITIVE RESULTS FROM PHASE 2A TRIAL OF ITK/JAK3 INHIBITOR ATI-2138 PRESENTED AT THE 2025 EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS, FURTHER VALIDATING ITK AS THERAPEUTIC TARGET; INITIATION OF PHASE 2 TRIAL IN AN ADDITIONAL INDICATION EXPECTED IN THE FIRST HALF OF 2026 - - TIMELINES REITERATED FOR TOP LINE CLINICAL RESULTS FROM ONGOING TRIALS OF INVESTIGATIONAL ANTI-TSLP MONOCLONAL ANTIBODY BOSAKITUG (ATI-045) AND ANTI-TSLP/IL-4R BISPECIFIC ANTIBODY ATI-052 - - INITIATION OF PHASE 1B PROOF-OF-CONCEPT TRIALS OF ATI-052 IN ASTHMA AND ATOPIC DERMATITIS (AD) EXPECTED IN THE FIRST HALF OF 2026 - - STRONG CASH RUNWAY EXPECTED TO FUND OPERATIONS INTO THE SECOND HALF OF 2028 - WAYNE, PA., NOV. 06, 2025 (GLOBE NEWSWIRE) -- ACLARIS THERAPEUTICS, INC. (NASDAQ: ACRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL PRODUCT CANDIDATES FOR IMMUNO-INFLAMMATORY DISEASES, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025 AND PROVIDED A CORPORATE UPDATE.

ACLARIS THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CONTINUED YEAR-OVER-YEAR SALES GROWTH DRIVEN BY AEROSPACE & DEFENSE RECORD AEROSPACE & DEFENSE SALES OF $793 MILLION, REPRESENTING 70% OF Q 3 2025 SALES STRONG MARGIN PERFORMANCE IN HPMC AND AA&S SEGMENTS RAISING FULL YEAR RANGES FOR ADJUSTED EARNINGS AND CASH FLOW GUIDANCE THIRD QUARTER 2025 GAAP FINANCIAL RESULTS SALES OF $1.13 BILLION, UP 7% YEAR-OVER-YEAR, DRIVEN BY A 21% AEROSPACE & DEFENSE INCREASE NET INCOME ATTRIBUTABLE TO ATI OF $110 MILLION, UP 33% YEAR-OVER-YEAR EARNINGS PER SHARE OF $0.78 COMPARED TO $0.57 PER SHARE IN THE THIRD QUARTER 2024 THIRD QUARTER 2025 NON-GAAP FINANCIAL INFORMATION* ADJUSTED NET INCOME ATTRIBUTABLE TO ATI* OF $119 MILLION, UP 39% YEAR-OVER-YEAR ADJUSTED EARNINGS PER SHARE* OF $0.85, COMPARED TO $0.60 PER SHARE IN THE THIRD QUARTER 2024 ADJUSTED EBITDA* OF $225 MILLION, AN INCREASE OF 21% YEAR-OVER-YEAR ADJUSTED EBITDA* AS A PERCENTAGE OF SALES OF 20.0%, COMPARED TO 17.7% IN THE THIRD QUARTER 2024 GUIDANCE THE COMPANY IS PROVIDING FOURTH QUARTER AND UPDATED FULL YEAR 2025 GUIDANCE IN THE TABLE BELOW. CURRENT GUIDANCE PRIOR GUIDANCE Q4 2025 FULL YEAR 2025 FULL YEAR 2025 ADJUSTED EBITDA** $221M - $231M $848M - $858M $810M - $840M ADJUSTED EARNINGS PER SHARE** $0.84 - $0.90 $3.15 - $3.21 $2.90 - $3.07 ADJUSTED FREE CASH FLOW** $330M - $370M $270M - $350M CAPITAL EXPENDITURES $260M - $280M $260M - $280M *RECONCILIATIONS OF THE REPORTED INFORMATION UNDER ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES (GAAP) TO NON-GAAP FINANCIAL MEASURES ARE INCLUDED IN ACCOMPANYING FINANCIAL TABLES.

ATI ANNOUNCES THIRD QUARTER 2025 RESULTS

TORONTO, OCT. 16, 2025 (GLOBE NEWSWIRE) -- ALTAI RESOURCES INC. (TSXV: ATI) (ALTAI OR THE COMPANY) ANNOUNCED TODAY THAT FURTHER TO THE COMPANY'S NEWS RELEASE DATED SEPTEMBER 4, 2025 REGARDING THE DECLARATION BY THE BOARD OF DIRECTORS OF THE COMPANY OF A SPECIAL CASH DISTRIBUTION OF $0.06 PER COMMON SHARE (THE SPECIAL CASH DISTRIBUTION), THE COMPANY HAS COMPLETED THE PAYMENT OF THE SPECIAL CASH DISTRIBUTION BY WAY OF A RETURN OF CAPITAL. THE TOTAL AMOUNT PAID BY THE COMPANY FOR THE SPECIAL CASH DISTRIBUTION WAS APPROXIMATELY $3.4 MILLION, WHICH WAS FUNDED FROM THE COMPANY'S CASH AND CASH EQUIVALENTS.AS OF TODAY'S DATE, THE COMPANY HAS APPROXIMATELY $0.7 MILLION OF CASH AND CASH EQUIVALENTS REMAINING, OR APPROXIMATELY $0.013 PER COMMON SHARE BASED ON THE TOTAL ISSUED AND OUTSTANDING COMMON SHARES OF 56,033,552. AS OF TODAY'S DATE, THE COMPANY IS DEBT-FREE.

ATI Inc.

ATI

Price

Financial Reports

No items found.

Press Releases

ATI Inc.

ATI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ATI